The Truth About 4 Popular Heart Health Supplements
Contract Research Organizations: Key Partners In The Drug Development Journey
Nick Lucas is Senior Vice President of Professional Services and Site Leader for EMEA at Medidata Solutions.
gettyOutsourcing of non-core services and resources is common practice in today's world as companies look to reduce overhead and costs and streamline their businesses. Pharmaceutical companies outsource their clinical research capabilities to contract research organizations (CROs) for a number of reasons, including therapeutic expertise of the CRO, cost benefits and geographic reach. But, ultimately, they do it to help bring new drugs and treatments to patients faster.
CROs have been around for decades — they first emerged in the 1940s and 1950s with the likes of Huntingdon Life Sciences and Charles River Laboratories. While CROs are the outsourcing partner for the life sciences sector, other industries are equally familiar with the concept. Tech companies, for example, have also been key proponents of outsourcing over the years. Skype used outsourcing services to create the back-end development of its app and Google has ramped up its outsourcing strategy, working with companies such as Cognizant.
CROs in clinical research range from global players who cover every part of the clinical trial process, every therapeutic area and every geography to smaller niche players who might specialize in a specific disease area. With over a thousand CROs worldwide, the CRO market is expected to grow by 12% in 2022 and reach $71.7 billion by 2024. While healthcare companies are well versed on the benefits of outsourcing, there are a number of key principles to adopt in order to maximize the success of using a CRO.
CROs Are Experts In Their Field
The Covid-19 pandemic has put the pharmaceutical industry in the spotlight, sparking increased levels of public interest in the clinical development process. It is widely recognized that the latest advances in the industry and the clinical successes during the pandemic would not have been possible without the help of CROs.
As experts, when it comes to niche areas and wider technologies, CROs are a valuable resource for pharmaceutical companies (or "sponsors"). They are quick to adopt the latest technologies, enabling them to provide unique insights and advice, spotting novel and distinctive ways of using these advanced tools and adapting them to each sponsor's needs to ensure optimal clinical trial performance. Some CROs even have their own unique technology offerings. The global CRO ICON, for example, develops technologies like PDx-Pop to integrate existing tools and its own methods to accelerate the process of population pharmacokinetic modeling and analysis.
In clinical trials, speed is fundamental, and this has been even more important in battling Covid-19, with pressure on the industry to deliver a vaccine in the shortest time possible. While sponsors play an important role in these clinical trials, the delivery wouldn't have been possible without the expanded expertise and vast resources brought by partnering with CROs. Johnson & Johnson, for example, has been leveraging IQVIA's virtual trial solutions for their Covid-19 vaccine trials. NonCovid-19 trials have been equally challenged by the restrictions caused by the pandemic, as patients have been unable to visit hospitals. In many cases, this was resolved through technology and the rapid uptake of virtual trials.
With the increase of personalized medicine and the one-size-fits-all model becoming obsolete, coupled with the industry drive to make trials more accessible and less burdensome for patients, technology has become a key element in clinical trials. CROs are at the forefront of implementing the latest technologies and tools available, both to maintain competitive advantage and ensure they're able to offer customers the full spectrum of available solutions. Given that the global CROs work with hundreds of sponsors, they have a learning curve and breadth of experience beyond any single sponsor (even a big pharma).
Setting Up For Success
CROs should be considered more than just useful resources — they should be thought of as partners in the drug development process. To ensure the partnership runs smoothly, sponsors should keep a few things in mind:
• Selection: Selecting the right CRO is crucial, as each CRO's expertise and reach varies. A thorough vetting process offers a chance to get an information download about the CRO and how they can help a sponsor meet their clinical objectives. CROs come in different shapes and sizes and different geographical spread or technical and therapeutic ability. Geographical reach or therapeutic focus can be very important in patient recruitment, especially if a trial requires a specific population group.
• Governance: Establishing an effective governance structure between parties is core to the success of the partnership. It must be underpinned by the allocation of roles and proper escalation procedures. Given the complexity of clinical trials, this ensures all parties can effectively manage the scope of a project and stay aligned on process, deliverables and expectations.
• Success metrics: A CRO and sponsor should determine how to monitor success to ensure they are both getting the most out of the partnership. Setting performance indicators is a good way of ensuring efficiency. While sponsors may be tempted to enforce specific standards or structures on CROs, adopting another organization's standards is often less effective than a CRO working to their own standards. This means putting trust in the CRO — they are the experts and know what they are doing.
• Communication: As with any partnership, communication is key. Having regular and transparent communication between all parties involved is absolutely crucial. This alone can help avoid most issues.
CROs Are Here To Stay
CROs have played an important role in the pharmaceutical industry over the past few decades and have grown to be more than a simple outsourcing resource. They are experts in the space, active partners in clinical research, and they are contributing massively to the industry's success. Sponsors should embrace these partnerships, and by establishing clear performance indicators and setting standards and a clear governance structure, they will be well on the way to a fruitful relationship.
In an industry where time is of the essence, CROs are a fantastic resource, and they play a key role in the success of many studies and in helping bring much-needed drugs and treatments to patients. Make the most of them.
Forbes Technology Council is an invitation-only community for world-class CIOs, CTOs and technology executives. Do I qualify?
Virtual Clinical Trials Market To Reach USD 13.17 Billion By 2031, Driven By The Need For Decentralized And Patient-Centric Clinical Research, Reports SNS Insider
IPS is an international communication institution with a global news agency at its core, raising the voices of the South and civil society on issues of development, globalisation, human rights and the environment Copyright © 2025 IPS-Inter Press Service. All rights reserved
Beyond The Numbers: 12 Analysts Discuss IQVIA Hldgs Stock
IQVIA Hldgs IQV underwent analysis by 12 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 5 3 0 0 Last 30D 0 0 1 0 0 1M Ago 1 1 1 0 0 2M Ago 0 0 1 0 0 3M Ago 3 4 0 0 0Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $227.67, a high estimate of $270.00, and a low estimate of $160.00. Highlighting a 9.81% decrease, the current average has fallen from the previous average price target of $252.42.
Understanding Analyst Ratings: A Comprehensive BreakdownAn in-depth analysis of recent analyst actions unveils how financial experts perceive IQVIA Hldgs. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
AnalystAnalyst FirmAction TakenRatingCurrent Price TargetPrior Price Target--------------------------------------------------------------------------------------------------------------Rajesh KumarHSBCLowersHold$160.00$260.00Jailendra SinghTruist SecuritiesLowersBuy$216.00$263.00Luke SergottBarclaysLowersEqual-Weight$170.00$235.00Ann HynesMizuhoLowersOutperform$210.00$242.00Patrick DonnellyCitigroupLowersNeutral$210.00$225.00Anne SamuelJP MorganLowersOverweight$232.00$240.00Tejas SavantMorgan StanleyRaisesOverweight$250.00$245.00Sean DodgeRBC CapitalMaintainsOutperform$270.00$270.00Jailendra SinghTruist SecuritiesRaisesBuy$263.00$261.00Shlomo RosenbaumStifelLowersBuy$261.00$273.00Dan LeonardUBSLowersBuy$255.00$260.00Luke SergottBarclaysLowersOverweight$235.00$255.00
Key Insights:To gain a panoramic view of IQVIA Hldgs's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on IQVIA Hldgs analyst ratings.
All You Need to Know About IQVIA HldgsIQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
IQVIA Hldgs: Financial Performance DissectedMarket Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: IQVIA Hldgs's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 2.33%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 11.04%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 6.71%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.62%, the company showcases effective utilization of assets.
Debt Management: IQVIA Hldgs's debt-to-equity ratio stands notably higher than the industry average, reaching 2.33. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
Understanding the Relevance of Analyst RatingsAnalysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.Com. Benzinga does not provide investment advice. All rights reserved.
Comments
Post a Comment